Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis
E. Wesley Ely(Vanderbilt University), Gordon R. Bernard(Vanderbilt University Medical Center), William L. Macias(Myovant Sciences (United States)), Pierre‐François Laterre(Cliniques Universitaires Saint-Luc), Howard Levy(Apple (Israel)), Jean-François Dhainaut(Université Paris Cité), Derek C. Angus(University of Pittsburgh), Jeffrey D. Helterbrand, Jean‐Louis Vincent(Université Libre de Bruxelles)
Cited by 283
Related Papers
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)
|JAMA|2016|28.1k
The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure
|Intensive Care Medicine|1996|11.7k
Surviving Sepsis Campaign
|Critical Care Medicine|2013|9.7k
Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012
|Intensive Care Medicine|2013|7.3k
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016
|Intensive Care Medicine|2017|6.8k